INTRAVITREAL DEXAMETHASONE IMPLANTATION IN PATIENTS WITH DIFFERENT MORPHOLOGICAL DIABETIC MACULAR EDEMA HAVING INSUFFICIENT RESPONSE TO RANIBIZUMAB

• Published in: Retina (Philadelphia, Pa.) Vol. 38; no. 5; p. 986
• Main Authors: Kaldırım, Havva, Yazgan, Serpil, Atalay, Kursat, Gurez, Ceren, Savur, Fatma
• Format: Journal Article
• Language: English
• Published: United States 01.05.2018
• Subjects: Aged; Dexamethasone - administration & dosage; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - physiopathology; Drug Implants; Female; Glucocorticoids - administration & dosage; Humans; Intravitreal Injections; Macular Edema - drug therapy; Macular Edema - physiopathology; Male; Middle Aged; Ranibizumab - therapeutic use; Retina - pathology; Retrospective Studies; Visual Acuity - physiology
• ISSN: 1539-2864
• DOI: 10.1097/IAE.0000000000001648

To evaluate the effectiveness of a single intravitreal injection of dexamethasone implant in resistant diabetic macular edema that have different morphological types. In this retrospective study, 31 patients (35 eyes) with persistent diabetic macular edema, who underwent a single injection of dexamethasone implant, were evaluated. Diabetic macular edema was classified into three types: diffuse retinal thickening (n = 10), cystoid macular edema (n = 13), and serous retinal detachment (n = 12). Primary outcome measures were best corrected visual acuity, and central macular thickness. The three subgroups were similar in terms of age and gender (P > 0.05). Total duration of diabetes was significantly less in the serous retinal detachment subgroup (P = 0.01). There were no differences in the best corrected visual acuity between the three subgroups until the sixth month. However, the best corrected visual acuity was significantly better in the diffuse retinal thickness subgroup at the sixth month (P = 0.008). Regarding the central macular thickness values, it was statistically better in serous retinal detachment than in diffuse retinal thickening and cystoid macular edema subgroups till the sixth month (P = 0.001). However, at the sixth month, there was not any statistical difference between subgroups regarding central macular thickness values. Antiglaucomatous agents were required in 4 (11.4%) patients throughout the study. Treatment algorithms should differ according to the morphology of diabetic macular edema; however, more data is needed to give specific recommendations.